Anaphylaxis Induced by Biologics

作者: Shyam R. Joshi , David A. Khan

DOI: 10.1007/S40521-019-00207-0

关键词:

摘要: Biologic agents are increasingly utilized in the medical management of many conditions. Their safety has become an important topic as a myriad reactions can occur due to immune-modulating properties these agents. Of these, anaphylaxis remains substantial concern, but its incidence and pathophysiology have not been comprehensively reviewed. Over past two decades, multitude case reports series published describing anaphylactic biologic agents, although true prevalence unknown for vast majority them. Based on cytokine mediator profiles, three mechanisms proposed: IgE-mediated, non-IgE-mediated, release. The clinical presentation is highly variable between degree humanization, excipient involvement, development process each agent all likely play role determining level allergenicity. As even more commonplace healthcare, thorough evaluations induced by BAs well underlying may provide clinically useful data when most appropriate option.

参考文章(89)
Phillip L. Lieberman, Dale T. Umetsu, Gillis J. Carrigan, Abdelkader Rahmaoui, Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study The Journal of Allergy and Clinical Immunology. ,vol. 138, pp. 913- 915 ,(2016) , 10.1016/J.JACI.2016.03.030
Browning Mc, Georgitis Jw, Lorentz Wb, Steiner D, Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection Annals of allergy. ,vol. 66, pp. 343- 347 ,(1991)
Polymyositis mediated by lymphocytes expressing the gamma/delta receptor. The New England Journal of Medicine. ,vol. 325, pp. 587- 588 ,(1991) , 10.1056/NEJM199108223250818
Paolo Campi, Maurizio Benucci, Mariangela Manfredi, Pascal Demoly, Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-α antagonists Current Opinion in Allergy and Clinical Immunology. ,vol. 7, pp. 393- 403 ,(2007) , 10.1097/ACI.0B013E3282EF96DF
Hariharan Subramanian, Kshitij Gupta, Hydar Ali, Roles of Mas-related G protein–coupled receptor X2 on mast cell–mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases The Journal of Allergy and Clinical Immunology. ,vol. 138, pp. 700- 710 ,(2016) , 10.1016/J.JACI.2016.04.051
J Mark FitzGerald, Eugene R Bleecker, Parameswaran Nair, Stephanie Korn, Ken Ohta, Marek Lommatzsch, Gary T Ferguson, William W Busse, Peter Barker, Stephanie Sproule, Geoffrey Gilmartin, Viktoria Werkström, Magnus Aurivillius, Mitchell Goldman, Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial The Lancet. ,vol. 388, pp. 2128- 2141 ,(2016) , 10.1016/S0140-6736(16)31322-8
Eugene R Bleecker, J Mark FitzGerald, Pascal Chanez, Alberto Papi, Steven F Weinstein, Peter Barker, Stephanie Sproule, Geoffrey Gilmartin, Magnus Aurivillius, Viktoria Werkström, Mitchell Goldman, Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial The Lancet. ,vol. 388, pp. 2115- 2127 ,(2016) , 10.1016/S0140-6736(16)31324-1
Njira Lugogo, Christian Domingo, Pascal Chanez, Richard Leigh, Martyn J. Gilson, Robert G. Price, Steven W. Yancey, Hector G. Ortega, Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study Clinical Therapeutics. ,vol. 38, pp. 2058- 2070 ,(2016) , 10.1016/J.CLINTHERA.2016.07.010
Benoît Dupont, Delphine Mariotte, Audrey E. Dugué, Bénédicte Clarisse, Jean-Michel Grellard, Emmanuel Babin, Bruno Chauffert, Stéphanie Dakpé, Cristian Moldovan, Karine Bouhier-Leporrier, Jean-Marie Reimund, Frederic Di Fiore, Sylvie Zanetta, Audrey Mailliez, Pascal Do, Annie Peytier, Marie-Pierre Galais, Carmen Florescu, Roland Schott, Brigitte Le Mauff, Radj Gervais, Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab. British Journal of Clinical Pharmacology. ,vol. 83, pp. 623- 631 ,(2017) , 10.1111/BCP.13140
Eric L Simpson, Thomas Bieber, Emma Guttman-Yassky, Lisa A Beck, Andrew Blauvelt, Michael J Cork, Jonathan I Silverberg, Mette Deleuran, Yoko Kataoka, Jean-Philippe Lacour, Külli Kingo, Margitta Worm, Yves Poulin, Andreas Wollenberg, Yuhwen Soo, Neil MH Graham, Gianluca Pirozzi, Bolanle Akinlade, Heribert Staudinger, Vera Mastey, Laurent Eckert, Abhijit Gadkari, Neil Stahl, George D Yancopoulos, Marius Ardeleanu, None, Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis The New England Journal of Medicine. ,vol. 375, pp. 2335- 2348 ,(2016) , 10.1056/NEJMOA1610020